Why the study?
Evidence of drug efficacy and safety in older people with cardiovascular disease, multimorbidity, and polypharmacy is limited, and guidelines rarely address complex prescribing challenges in this population.
Design
Review
Key result
Cardiovascular pharmacotherapy in older adults with multimorbidity and polypharmacy is complex and lacks sufficient clinical trial evidence, requiring improved prescribing strategies.
Authors
Loading...
Urges cautious individualized prescribing in older adults with multimorbidity; leaves open the need for targeted trials to close evidence gaps.
This ESC Working Group review emphasizes the critical need for tailored prescribing strategies and better clinical guidelines to manage polypharmacy and multimorbidity in older patients with cardiovascular disease.
Tamargo et al. (2022) conducted a review in Cardiovascular disease, multimorbidity, and polypharmacy. Polypharmacy and cardiovascular pharmacotherapy was evaluated. Cardiovascular pharmacotherapy in older adults with multimorbidity and polypharmacy is complex and lacks sufficient clinical trial evidence, requiring improved prescribing strategies.